Update on Import and Circulation of Foreign Medicines after 1 July 2024
We are happy to announce that one of the issues relating to introduction of mandatory marking of medicines by the identification means in Kazakhstan has been solved.
Specifically, an important issue[i] regarding possibility to import unmarked medicines manufactured before 1 July 2024 to Kazakhstan after 1 July 2024 was settled by introducing amendments[ii] into the List of Goods Subject to Marking.
Since 1 July 2024, subject to mandatory marking by the identification means are the medicines manufactured starting from 1 July 2024, packed in the dosage forms (including medicines in the form of transdermal systems) or in the form or packages for retail sale, except for the medicines and vaccines applied in veterinary practice (EAEU CN of FEA codes are specified in the List).
Thus, medicines manufactured BEFORE 1 July 2024 both in Kazakhstan and abroad may be imported into Kazakhstan after this date and further circulate on the Kazakhstan market without applying special marking by the identification means. Such medicines are not subject to mandatory marking by the identification means in Kazakhstan.
[i] This issue was considered in detail in the article by AEQUITAS Counsel Larissa Yemelyanova "Import and circulation of foreign "remnants" of medicines after 1 July 2024" (4 March 2024).
[ii] Decree No. 516 of the Government of the Republic of Kazakhstan "On Introduction of Amendment into the Decree No. 568 of the Government of the Republic of Kazakhstan of 10 September 2020 on Determining the List of Goods Subject to Marking" dated 28 June 2024.
![](/images/qr.png)